24 August 2020 Blog Post: COVID-19 Update Absolute versus Relative Risk

The Trump Administration today has taken up the call of the convalescent serum “breakthrough” by spreading the notion that this treatment would save 30-50 individuals out of 100 infected with COVID-19. This is false and those saying such have made a fundamental error in mistaking absolute risk for relative risk. Relative risk is a basic Epidemiologic concept covered in any first year, introductory class.
 
Some examples of the false soundbites:
 
1. Michael Caputo (Health and Human Services Assistant Director – no medical training): “If you’re one of the 35 people out of a hundred who survive severe COVID symptoms because of convalescent plasma, you’re damn right this is a BREAKTHROUGH.”
2. Alyssa Farah (White House Director of Communications – BA in Journalism and Public Policy, no medical training): “Mayo Clinic shows Convalescent Plasma will reduce mortality from COVID by as much as 30 to 50%. These are REAL American lives that will be saved as a result of this EUA.”
 
The Mayo Clinic study reported that convalescent serum reduced the 7-day death rate from 11.9% to 8.7%, not that it would “stop” 35 out of 100 deaths. In reality, 3 more people out of 100 may survive when treated, not 35. Or, to put more bluntly, 97 of 100 would still be expected to die.
 
Convalescent serum is not a miracle. Treatment of severe COVID-19 manifestations are best treated with prone positioning, oxygen support, dexamethasone, antithrombotics to prevent clots, and remdesivir (an antiviral originally developed for Ebola). Convalescent serum still has a role in compassionate use scenarios – but 97 out of 100 patients relying on its efficacy alone will still die.
 
Those are facts.

𝗦𝗶𝗴𝗻 𝗨𝗽 𝗳𝗼𝗿 𝗢𝘂𝗿 𝗡𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿

Dig deeper into the health topics you care about most by signing up for our newsletter.

by submitting this form you indicate you have
read and agree to our Privacy Policy and Terms
of Use. Please contact us to for us for more
information.

Recommended Posts

No comment yet, add your voice below!


Add a Comment

Your email address will not be published. Required fields are marked *